Foghorn appoints Kristian Humer as CFO; notes upcoming pipeline milestones for 2024

Foghorn Therapeutics Inc.

Kristian Humer appointed CFO effective April 16, replacing interim CFO Stephen DiPalma.
Compensation: $475k base salary, 40% target bonus, $87k signing bonus, 275k-share option award.
Humer brings 14+ years life science financial strategy; previously CFO/CBO at Viridian Therapeutics.
Lead program FHD-286 AML data expected H2 2024; FHD-909 (with Lilly) IND filing on track Q2 2024.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Stephen DiPalma

Interim Chief Financial Officer

FHTX · Foghorn Therapeutics Inc.

Effective: 2024-04-16
Successor: Kristian F. Humer
Filed: April 16, 2024, 7:59 PM ET

In connection with Mr. Humer’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, will cease to serve in such roles.

Appointed

Kristian F. Humer

Chief Financial Officer

FHTX · Foghorn Therapeutics Inc.

Effective: 2024-04-16
Filed: April 16, 2024, 7:59 PM ET

On April 16, 2024, Foghorn Therapeutics Inc. (the “Company”) announced that Kristian F. Humer had been appointed to serve as the Company’s Chief Financial Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Stephen DiPalma departed as Interim Chief Financial Officer at Foghorn Therapeutics Inc..

Action: ceased to serve
Role: Interim Chief Financial Officer

Exact text from the filing

In connection with Mr. Humer’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, will cease to serve in such roles.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kristian F. Humer was appointed as Chief Financial Officer at Foghorn Therapeutics Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On April 16, 2024, Foghorn Therapeutics Inc. (the “Company”) announced that Kristian F. Humer had been appointed to serve as the Company’s Chief Financial Officer, effective immediately.

View on SEC.gov

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-016281

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.